Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00406588 · ClinicalTrials.gov registry record · Phase 3
SLV308 for Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations
A Phase 3 study of Advanced Stage Parkinson's Disease, sponsored by Solvay Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 295
- Enrollment target
- 20
- Study locations
NCT00406588 is a Phase 3 study of Advanced Stage Parkinson's Disease that has completed, run by Solvay Pharmaceuticals. The registered enrollment target is 295 participants. The trial reports 20 study locations across 13 states.
The verdict
NCT00406588, a Phase 3 study of Advanced Stage Parkinson's Disease, has completed, sponsored by Solvay Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 295 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is a multicenter, randomized, double blind, parallel group study of 3 months' treatment with SLV308 administered as a monotherapy in patients with advance stage PD. An open label safety extension to this study is planned as a separate protocol for patients who are willing and eligible to participate.
Conditions Studied
Interventions
- DRUG Placebo Comparator
- DRUG Levodopa (Pardoprunox)
Study Locations (20)
Other
- Site 100 - Buenos Aires
- Site 101 - Buenos Aires
- Site 102 - Buenos Aires
- Site 103 - Buenos Aires
- Site 106 - Buenos Aires
Florida
- Site 214 - Fort Lauderdale
- Site 218 - Gainsville
- Site 213 - Tampa
California
- Site 220 - La Jolla
- Site 211 - San Francisco
Alabama
- Site 223 - Birmingham
Georgia
- Site 219 - Augusta
Illinois
- Site 221 - Chicago
Kansas
- Site 216 - Kansas City
Kentucky
- Site 224 - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 295 participants |
| Start Date | 2007-03 |
| Est. Completion | 2008-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00406588
The ClinicalTrials.gov registry entry for NCT00406588 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 295 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Solvay Pharmaceuticals, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Stage Parkinson's Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo Comparator is the first listed.
NCT00406588 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Other, Florida, California.
Frequently Asked Questions
What is clinical trial NCT00406588 about?
NCT00406588 is a clinical study titled "SLV308 for Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations". This study is a multicenter, randomized, double blind, parallel group study of 3 months' treatment with SLV308 administered as a monotherapy in patients with advance stage PD. An open label safety extension to this study is planned as a separate protocol for patients who are willing and eligible to ...
What is the current status of trial NCT00406588?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 295 participants. The study started on 2007-03. Estimated completion is 2008-05.
What conditions does trial NCT00406588 study?
This clinical trial studies the following conditions: Advanced Stage Parkinson's Disease.
What interventions are being tested in trial NCT00406588?
The interventions under investigation include: Placebo Comparator (DRUG), Levodopa (Pardoprunox) (DRUG).
Who is sponsoring clinical trial NCT00406588?
This trial is sponsored by Solvay Pharmaceuticals, which has 35 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00406588 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.